Abstract
Telomerase is an enzyme that has been attracting much attention in recent years because its activities are so central to the processes of malignant transformation. It is a reverse transcriptase enzyme that can synthesize telomeric DNA using its own RNA component as a template. Without telomerase, telomeres will shorten until, at a critical length, cells enter senescence and die. The low level or absence of telomerase activity in most nonneoplastic tissues and somatic cells, and its presence in almost all malignant tumors is thus of great interest for potential diagnostic, prognostic, and therapeutic applications in the management of human cancer. It has been documented that high telomerase activity and short telomere length correlate with poor prognosis in patients with multiple myeloma, and antitelomerase therapy has become a novel therapeutic approach for the disease. Thus, determination of telomerase activity and telomere length is essential in the study of cancer. In this chapter, we provide a standard telomeric repeat amplification protocol for telomerase activity assay and a Southern blot terminal restriction fragment protocol for telomere length assay. We also discuss comparison with related assay methods.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lansdorp P. M., Verwoerd N. P., van de Rijke F. M., et al. (1996) Heterogeneity in telomere length of human chromosomes. Hum. Mol. Genet. 5, 685ā691.
Sandell L. L. and Zakian V. A. (1993) Loss of a yeast telomere: arrest, recovery, and chromosome loss. Cell 75, 729ā739.
Kirk K. E., Harmon B. P., Reichardt I. K., Sedat J. W., and Blackburn E. H. (1997) Block in anaphase chromosome separation caused by a telomerase template mutation. Science 275, 1478ā1481.
Watson J. D. (1972) Origin of concatemeric T7 DNA. Nat. N. Biol. 239, 197ā201.
Collins K. and Mitchell J. R. (2002) Telomerase in the human organism. Oncogene 21, 564ā579.
Harley C. B. (2002) Telomerase is not an oncogene. Oncogene 21, 494ā502.
MacKenzie K. L., Franco S., Naiyer A. J., et al. (2002) Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene 21, 4200ā4211.
Wu K. D., Orme L. M., Shaughnessy J., Jr., Jacobson J., Barlogie B., and Moore M. A. (2003) Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 101, 4982ā4989.
Xu D., Zheng C., Bergenbrant S., et al. (2001) Telomerase activity in plasma cell dyscrasias. Br. J. Cancer 84, 621ā625.
Shiratsuchi M., Muta K., Abe Y., et al. (2002) Clinical significance of telomerase activity in multiple myeloma. Cancer 94, 2232ā2238.
Wang E. S., Wu K., Chin A. C., et al. (2004) Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 103, 258ā266.
Akiyama M., Hideshima T., Shammas M. A., et al. (2003) Effects of oligonucleotide N3'āP5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 63, 6187ā6194.
Kim N. W., Piatyszek M. A., Prowse K. R., et al. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011ā2015.
Wright W. E., Shay J. W., and Piatyszek M. A. (1995) Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res. 23, 3794ā3795.
Allsopp R. C., Vaziri H., Patterson C, et al. (1992) Telomere length predicts replicative capacity of human fibroblasts. Proc. Natl. Acad. Sci. USA 89, 10,114ā10,118.
Allshire R. C., Dempster M., and Hastie N. D. (1989) Human telomeres contain at least three types of G-rich repeats distributed non-randomly. Nucleic Acids Res. 17, 4611ā4627.
Harley C., Futcher A., and Greider C. (1990) Telomeres shorten during ageing of human fibroblasts. Nature 345, 458ā460.
de Lange T., Shiue L., Myers R. M., et al. (1990) Structure and variability of human chromosome ends. Mol. Cell Biol. 10, 518ā527.
Feng Y. R., Biggar R. J., Gee D., Norwood D., Zeichner S. L., and Dimitrov D. S. (1999) Long-term telomere dynamics: modest increase of cell turnover in HIV-infected individuals followed for up to 14 years. Pathobiology 67, 34ā38.
Norwood D. and Dimitrov D. S. (1998) Sensitive method for measuring telomere lengths by quantifying telomeric DNA content of whole cells. Biotechniques 25, 1040ā1045.
Rufer N., Dragowska W., Thornbury G., Roosnek E., and Lansdorp P. M. (1998) Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat. Biotechnol. 16, 743ā747.
Baerlocher G. M., Mak J., Tien T., and Lansdorp P. M. (2002) Telomere length measurement by fluorescence in situ hybridization and flow cytometry: tips and pitfalls. Cytometry 47, 89ā99.
Lauzon W., Dardon S. J., Cameron D. W., and Badley A. D. (2000) Flow cytometric measurement of telomere length. Cytometry 42, 159ā164.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2005 Humana Press Inc.
About this protocol
Cite this protocol
Wu, Kd., Moore, M.A.S. (2005). Determination of Telomerase Activity and Telomere Length. In: Brown, R.D., Ho, P.J. (eds) Multiple Myeloma. Methods in Molecular Medicineā¢, vol 113. Humana Press. https://doi.org/10.1385/1-59259-916-8:207
Download citation
DOI: https://doi.org/10.1385/1-59259-916-8:207
Publisher Name: Humana Press
Print ISBN: 978-1-58829-392-3
Online ISBN: 978-1-59259-916-5
eBook Packages: Springer Protocols